Compare Stocks: OSTX, FATE, LCTX, and FHTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$2.76 -1.4%	$2.47	$0.91 ▼ $3.23	$321.70M	2.52	2.37 million shs	1.95 million shs
FHTX Foghorn Therapeutics	$6.24 +2.8%	$4.77	$3.27 ▼ $6.95	$360.47M	2.89	224,655 shs	366,760 shs
LCTX Lineage Cell Therapeutics	$1.13 +2.7%	$1.20	$0.97 ▼ $2.09	$278.20M	1.53	982,110 shs	752,317 shs
OSTX OS Therapies	$1.63 +1.9%	$1.69	$1.15 ▼ $2.57	$72.86M	-0.72	336,987 shs	174,839 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	-1.43%	+10.40%	-10.97%	+22.67%	+199.54%
FHTX Foghorn Therapeutics	+2.80%	+35.36%	+4.87%	+47.17%	+36.24%
LCTX Lineage Cell Therapeutics	+2.73%	+1.80%	-11.72%	-15.04%	+14.79%
OSTX OS Therapies	+1.87%	+5.16%	-2.98%	-4.68%	-5.78%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$2.76 -1.4%	$2.47	$0.91 ▼ $3.23	$321.70M	2.52	2.37 million shs	1.95 million shs
FHTX Foghorn Therapeutics	$6.24 +2.8%	$4.77	$3.27 ▼ $6.95	$360.47M	2.89	224,655 shs	366,760 shs
LCTX Lineage Cell Therapeutics	$1.13 +2.7%	$1.20	$0.97 ▼ $2.09	$278.20M	1.53	982,110 shs	752,317 shs
OSTX OS Therapies	$1.63 +1.9%	$1.69	$1.15 ▼ $2.57	$72.86M	-0.72	336,987 shs	174,839 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	-1.43%	+10.40%	-10.97%	+22.67%	+199.54%
FHTX Foghorn Therapeutics	+2.80%	+35.36%	+4.87%	+47.17%	+36.24%
LCTX Lineage Cell Therapeutics	+2.73%	+1.80%	-11.72%	-15.04%	+14.79%
OSTX OS Therapies	+1.87%	+5.16%	-2.98%	-4.68%	-5.78%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FATE Fate Therapeutics	2.29	Hold	$5.13	85.69% Upside
FHTX Foghorn Therapeutics	2.88	Moderate Buy	$11.43	83.15% Upside
LCTX Lineage Cell Therapeutics	3.00	Buy	$6.25	453.10% Upside
OSTX OS Therapies	2.75	Moderate Buy	$13.33	718.00% Upside

Current Analyst Ratings Breakdown

Latest OSTX, FATE, LCTX, and FHTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2026	FHTX Foghorn Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	LCTX Lineage Cell Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/9/2026	OSTX OS Therapies	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
7/9/2026	OSTX OS Therapies	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
6/8/2026	FATE Fate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00
6/4/2026	OSTX OS Therapies	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
5/19/2026	FATE Fate Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$4.00
5/19/2026	FATE Fate Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
5/19/2026	OSTX OS Therapies	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$14.00 ➝ $13.00
5/13/2026	FATE Fate Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FATE Fate Therapeutics	$6.32M	50.93	N/A	N/A	$1.80 per share	1.53
FHTX Foghorn Therapeutics	$30.91M	11.99	N/A	N/A	($1.92) per share	-3.25
LCTX Lineage Cell Therapeutics	$14.56M	19.63	N/A	N/A	$0.19 per share	5.95
OSTX OS Therapies	N/A	N/A	N/A	N/A	($0.17) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FATE Fate Therapeutics	-$136.32M	-$1.09	N/A	N/A	N/A	-2,056.79%	-58.89%	-39.39%	8/11/2026 (Estimated)
FHTX Foghorn Therapeutics	-$74.28M	-$0.98	N/A	N/A	N/A	-175.78%	N/A	-31.17%	N/A
LCTX Lineage Cell Therapeutics	-$63.53M	-$0.12	N/A	N/A	N/A	-246.58%	-82.83%	-31.04%	N/A
OSTX OS Therapies	-$28.75M	-$0.79	N/A	2.63	N/A	N/A	N/A	-422.43%	N/A

Latest OSTX, FATE, LCTX, and FHTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	FATE Fate Therapeutics	-$0.2682	N/A	N/A	N/A	$1.37 million	N/A
8/6/2026	Q2 2026	FHTX Foghorn Therapeutics	-$0.2450	-$0.10	+$0.1450	-$0.10	$6.81 million	$16.10 million
8/6/2026	Q2 2026	LCTX Lineage Cell Therapeutics	-$0.0283	-$0.03	-$0.0017	-$0.03	$1.84 million	$1.07 million
5/18/2026	Q1 2026	OSTX OS Therapies	N/A	-$0.27	N/A	-$0.27	N/A	N/A
5/13/2026	Q1 2026	FATE Fate Therapeutics	-$0.29	-$0.26	+$0.03	-$0.26	$1.49 million	$1.30 million
5/12/2026	Q1 2026	LCTX Lineage Cell Therapeutics	-$0.02	-$0.03	-$0.01	-$0.03	$3.60 million	$1.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
LCTX Lineage Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FATE Fate Therapeutics	N/A	5.85	5.85
FHTX Foghorn Therapeutics	N/A	3.36	3.36
LCTX Lineage Cell Therapeutics	N/A	6.89	6.89
OSTX OS Therapies	N/A	0.05	0.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FATE Fate Therapeutics	97.54%
FHTX Foghorn Therapeutics	61.55%
LCTX Lineage Cell Therapeutics	62.47%
OSTX OS Therapies	N/A

Insider Ownership

Company	Insider Ownership
FATE Fate Therapeutics	4.74%
FHTX Foghorn Therapeutics	9.02%
LCTX Lineage Cell Therapeutics	24.70%
OSTX OS Therapies	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FATE Fate Therapeutics	550	116.56 million	111.03 million	Optionable
FHTX Foghorn Therapeutics	120	59.38 million	54.03 million	Optionable
LCTX Lineage Cell Therapeutics	60	252.91 million	190.44 million	Not Optionable
OSTX OS Therapies	N/A	45.54 million	41.17 million	N/A

OSTX, FATE, LCTX, and FHTX Headlines

Recent News About These Companies

OS Therapies Settles Leonite Debt, Issues Bridge Financing

August 6, 2026 | tipranks.com

OS Therapies (NYSEAMERICAN:OSTX) Stock Price Down 2.6% - Here's What Happened

August 1, 2026 | americanbankingnews.com

OS Therapies (NYSEAMERICAN:OSTX) Shares Down 2.6% - Here's What Happened

August 1, 2026 | marketbeat.com

OS Therapies Ends At-The-Market Equity Sales Program

July 29, 2026 | tipranks.com

OS Therapies is a buy, this analyst says

July 15, 2026 | cantechletter.comC

OS Therapies Corporate Event Calendar | AMEX:OSTX

July 9, 2026 | benzinga.com

OS Therapies: OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program

July 8, 2026 | finanznachrichten.de

OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program

July 8, 2026 | newsfilecorp.comN

Why OS Therapies Incorporated’s (OSTX) Stock Is Down 10.11%

July 6, 2026 | aaii.comA

OS Therapies: OS Therapies Third Quarter 2026 Corporate Outlook

July 6, 2026 | finanznachrichten.de

OS Therapies Third Quarter 2026 Corporate Outlook

July 6, 2026 | newsfilecorp.comN

OS Therapies: OS Therapies Appoints Dr. Craig Eagle to Board of Directors

July 2, 2026 | finanznachrichten.de

OS Therapies Secures Convertible Note Financing for Expansion

July 2, 2026 | tipranks.com

OS Therapies Appoints Dr. Craig Eagle to Board of Directors

July 2, 2026 | newsfilecorp.comN

OS Therapies Provides U.S. Regulatory Update

June 30, 2026 | newsfilecorp.comN

OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma

June 26, 2026 | newsfilecorp.comN

OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma

June 8, 2026 | newsfilecorp.comN

OS Therapies: OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma

June 2, 2026 | finanznachrichten.de

OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma

June 2, 2026 | newsfilecorp.comN

OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World

May 29, 2026 | newsfilecorp.comN

OS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol “OSTX”

May 28, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSTX, FATE, LCTX, and FHTX Company Descriptions

Fate Therapeutics NASDAQ:FATE

$2.76 -0.04 (-1.43%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$2.81 +0.05 (+1.67%)

As of 07:14 AM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Foghorn Therapeutics NASDAQ:FHTX

$6.24 +0.17 (+2.80%)

As of 08/10/2026 04:00 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

$1.13 +0.03 (+2.73%)

Closing price 08/10/2026 04:10 PM Eastern

Extended Trading

$1.12 -0.01 (-1.33%)

As of 06:59 AM Eastern

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

OS Therapies NYSEAMERICAN:OSTX

$1.63 +0.03 (+1.88%)

Closing price 08/10/2026 04:10 PM Eastern

Extended Trading

$1.62 0.00 (-0.31%)

As of 04:35 AM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OSTX, FATE, LCTX, and FHTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OSTX, FATE, LCTX, and FHTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OSTX, FATE, LCTX, and FHTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSTX, FATE, LCTX, and FHTX Company Descriptions

Fate Therapeutics NASDAQ:FATE

Foghorn Therapeutics NASDAQ:FHTX

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

OS Therapies NYSEAMERICAN:OSTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OSTX, FATE, LCTX, and FHTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OSTX, FATE, LCTX, and FHTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OSTX, FATE, LCTX, and FHTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSTX, FATE, LCTX, and FHTX Company Descriptions

Fate Therapeutics NASDAQ:FATE

Foghorn Therapeutics NASDAQ:FHTX

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

OS Therapies NYSEAMERICAN:OSTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools